Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

colorectacl cancer

- PMLiVE

FDA priority review granted for J&J, Legend Biotech’s myeloma CAR T therapy

CAR T therapy demonstrated an overall response rate of 97% in relapsed/refractory multiple myeloma patients after 12.4 months

Roche Basel Switzerland

EC approves Venclyxto-based combinations for newly diagnosed AML

The treatment is approved for newly diagnosed acute myeloid leukaemia patients who can’t receive intensive chemotherapy

Roche Basel Switzerland

Roche’s Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients

Interim results from the phase 3 study to be presented at ASCO 2021

- PMLiVE

Detailed results for Regeneron’s antibody cocktail continue to show benefit in high-risk COVID-19 outpatients

Treatment shortened symptom duration and reduced viral load in non-hospitalised patients with COVID-19

- PMLiVE

FDA approves Apellis’ Empaveli for rare blood disease

PEGASUS study results show Empaveli is better than Soliris at improving haemoglobin levels

- PMLiVE

New court filing alleges Sanofi destroyed emails relating to Zantac recall

Drugmaker began recalling heartburn drug in 2019 after link to probable human carcinogen

- PMLiVE

Prothena achieves $60m milestone as part of Roche collaboration

Milestone reached as first patient doses in phase 2b trial of prasinezumab in early Parkinson's disease patients

- PMLiVE

Emergency authorisation for Pfizer/BioNTech vaccine expanded in the US

Data from a study involving 12 to 15 year olds has also been submitted to the EMA for potential approval

- PMLiVE

Pfizer, BioNTech file for full US approval of COVID-19 vaccine

Pfizer chief executive Albert Bourla said last week the company is on track to supply 2.7bn doses in 2021

- PMLiVE

FDA approval for Keytruda/Herceptin combination in first-line advanced gastric cancer

Approval is based on positive overall response rate (ORR) data from KEYNOTE-811 trial

- PMLiVE

bluebird bio aiming to separate business units by year-end

Biotech company has revealed that its new, separate oncology company will be named 2seventy bio

- PMLiVE

J&J resumes US rollout of single-dose COVID-19 vaccine

CDC and FDA recommended pause be lifted after ‘rigorous review’ of very rare blood clots

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links